Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

(Shutterstock)
Key Takeaways
  • Pfizer discontinued development of the oral GLP-1 agonist danuglipron for obesity due to a single case of acute liver injury in a pharmacokinetic trial.

Investor outlook for Pfizer’s oral GLP-1 agonist danuglipron was already dampened, but now the obesity drug has officially been discontinued,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Business

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.